Dr Peter Senior

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | New England Journal of Medicine www.nejm.org/doi/full/10....

Hope this proves as transformative as the Edmonton Protocol

Delighted to see CanScreenT1D added to the map

Nerea Cuesta Gomez presenting her work at IPITA in Pisa @albertadiabetes.bsky.social @ualberta.bsky.social #diabetes

U of A celebrates 25th anniversary of the Edmonton Protocol, advancing diabetes treatment | CityNews Edmonton Verlyn Olsen has experienced terrifying moments since being diagnosed with type 1 diabetes in the 80s.

edmonton.citynews.ca/2025/06/05/u...

So excited to hear about Hypoimmune islet transplants from Sonja Schrepfer from Sana Biotechnology - without immunosuppression
Is this the future for cell therapy in diabetes?
@albertadiabetes.bsky.social celebrating the 25th anniversary of the Edmonton Protocol #25EP

One more sleep

We are delighted to welcome you to the @albertadiabetes.bsky.social institute

Could a pill cure diabetes? A U of A researcher is working on it A simple pill to treat or even cure diabetes could be possible, thanks to University of Alberta research — and funding that is laying vital groundwork.

Excited to enroll our first participant for testing an agent (tolimidone) we hope will promote beta cell regeneration, building on preclinical work from Dr Jean Buteau at @albertadiabetes.bsky.social. Supported by Alberta Diabetes Foundation & biodexa pharmaceuticals www.ualberta.ca/en/folio/202...

Interested to hear highlights from this years ATTD? Join the webinar on Tuesday 20th May at 7.30 eastern. Register now

Medical Affairs team hosts international islet cell therapy workshops Our Medical Affairs team hosted cell therapy workshops with islet transplant experts to discuss a roadmap for manufactured cell therapies.

Excited to contribut to this exciting work
www.breakthrought1d.org/news-and-upd...

4 weeks until our celebration of the 25th anniversary of the Edmonton Protocol. Still time to register for the public event and scientific symposium.
#diabetes #islet @AlbertaDiabetes

www.ualberta.ca/en/alberta-d...

Health Canada approves Tzield – the first ever disease modifying therapy for type 1 diabetes | Breakthrough T1D On May 5, 2025, Sanofi announced Health Canada approval of Tzield, the first disease-modifying therapy for type 1 diabetes (T1D). This is a huge win for the T1D community in that it is the first medic...

breakthrought1d.ca/news/health-...

some studies use assays which are very sensitive and how much c-peptide you need to make a meaningful difference is still debated.
Probably 0.2nmol/L (= 200pmol/l or 0.6 ng/ml) is helpful

Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes OBJECTIVE. It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for trea

16% of adult-onset and 6% of childhood-onset cases had residual C-peptide even >40 years from diagnosis

diabetesjournals.org/care/article...

Did you know that some people with #T1D still have surviving insulin producing #betacells - even years after diagnosis.
Future treatments to regenerate these beta cells could help treat #T1D
#Cpeptide is measured by a simple blood test and can detect surviving beta cells

Could a pill cure diabetes? A U of A researcher is working on it A simple pill to treat or even cure diabetes could be possible, thanks to University of Alberta research — and funding that is laying vital groundwork.

The Alberta Diabetes Institute has some amazing researchers making important discoveries. www.ualberta.ca/en/folio/202...
We want to see if they work in people - beginning with #T1D who still have some C-peptide. To hear more www.ualberta.ca/en/alberta-d...

Type 1 diabetes screening: need for ethical, equity, and health systems perspective As of October, 2024, the ICD-10 codes include presymptomatic type 1 diabetes, whereas previously these codes only included type 1 diabetes once it was diagnosed. The codes now present the different st...

www.thelancet.com/journals/lan...
Importance of the patient voice in #t1d #screening

Since yesterday

Glycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice Guideline This updated clinical practice guideline replaces the previous chapter of Glycemic Management in Adults With Type 1 Diabetes (2018, chapter 12) and updates the glycemic management portions of the Mana...

So excited it is finally out, the new Diabetes Canada Clinical Practice Guidelines Chapter on Glycemic Management Across the Lifespan for Type 1 Diabetes. Give it a read of #T1D impacts your life www.canadianjournalofdiabetes.com/article/S149...

Perhaps not the best placement for this ad for inhaled insulin

Really excited to announce our event celebrating the 25th anniversary of publication of the #EdmontonProtocol #25EP #T1D #islet_cells

Just wondering about the trauma of recurrent “near misses” - which doctors term non-severe hypoglycemia in #T1D

Great Day. Great People. Important work.
Thanks @breakthrought1dhq.bsky.social

Come and work with us at the Alberta Diabetes Institute. We are connecting people with T1D and researchers to accelerate innovation to improve the lives of people with diabetes. We need a project lead to help us. apps.ualberta.ca/careers/post...

Shipments out. Supporting 20 research projects across Canada, North America, Europe and Asia. We have room for more. Give us a shout if you need islets, pancreas, intestine, adipose…. for research. https://www.bcell.org/faqs.html

Finally made a Canadian Diabetes Research starter pack! Join our fun community and follow these talented colleagues. 🧪https://go.bsky.app/PFHwQS

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study We have developed a five-drug class model that uses routine clinical data to identify optimal glucose-lowering therapies for people with type 2 diabetes. Individuals on model-predicted optimal therapy...

Published in @thelancet.bsky.social

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 #diabetes: a prediction model development and validation study www.thelancet.com/journals/lan... #T2D
#OpenAccess
#MedSky #EndoSky

Characterization of islet cells from people with type 1 #diabetes underscores the complex interplay between immune signaling, metabolic stress, and cellular identity in shaping islet cell phenotypes in #T1D @bcellorg.bsky.social www.biorxiv.org/content/10.1... @albertadiabetes.bsky.social